Focuses and supplements


Nature Biotechnology periodically publishes special supplements and focuses on timely topics of particular interest. This page provides an index of the different supplements and focuses that we have released over the past few years.


Top

2017

RNA-based therapies

RNA-based therapies

A joint focus with Nature Reviews Drug Discovery on RNA-based therapeutics presents a series of articles detailing recent progress in chemistries and delivery technologies that have propelled the clinical advancement of oligonucleotide therapies as well as highlighting commercial advances in RNA vaccines.


Top

2016

Single-cell Technology

Single-cell Technology

Single cell technologies are becoming increasingly important tools in biological analysis. Complementing average measurements on bulk populations of cells, single-cell measurements provide a finer-grained picture of complex biology and unmask heterogeneity that is present in tissues. With the increasing sophistication of microfluidics, electrophysiology measurements, high-resolution imaging, deep sequencing and mass spectrometry platforms, a more detailed picture of cellular subtype, physical location in tissue, and clonal evolution is emerging. Moreover, the exquisite sensitivity of these approaches is enabling the identification of rare cells of potential functional or pathogenic consequence. This mini-focus brings together a set of article that explores key issues in analyzing, integrating and applying single-cell data with an emphasis on challenges for the field.

Computational Biology

Computational Biology

Advances in technology across all areas of science have ushered in an era of big data, providing researchers with unprecedented opportunities to understand how biological systems function and interact. Scientists are now faced with the challenge of developing sophisticated computational tools capable of unravelling these data and uncovering important biological signals. Computational biology will continue to play a key role in facilitating multi-disciplinary collaborations, encouraging data sharing and establishing experimental and analytical standards in the life sciences. Produced with support from IBM Research and IBM Watson Health.


Nature Biotechnology 20th Anniversary

Nature Biotechnology 20th Anniversary

Nature Biotechnology is 20! We have brought together a collection of Features celebrating two decades of the science and business of biotech, with an eye on the future.

March Vol. 34, No. 3


Top

2014

SEQC Collection

SEQC

A Web Collection of articles from Nature Biotechnology, Nature Communications and Scientific Data presents results from The RNA Sequencing Quality Control (SEQC) project. This project sought to both evaluate the comparability of RNA-seq data from different laboratories and assess the performance of different sequencing platforms and data analysis approaches against DNA microarrays. Produced with support from the FDA's National Center for Toxicological Research (NCTR/FDA) and the State Key Laboratory of Genetic Engineering (SKLGE) at Fudan University.


RNA sequencing quality control (SEQC)

RNA sequencing quality control (SEQC)

The RNA Sequencing Quality Control project evaluates the comparability of RNA-seq data from different laboratories and assesses the performance of different sequencing platforms and data analysis approaches against DNA microarrays.

September Vol. 32, No. 9


Regenerative Medicine

Regenerative Medicine

Research in regenerative medicine is advancing toward the goal of repairing damaged tissue and organs. Nature Biotechnology and Nature Medicine present a collection of reviews, features and commentaries that explore our current mechanistic understanding of stem cells, and the emerging technologies that will bring regenerative medicine to the clinic.

August Vol. 32, No. 8


High dimensional immune analysis

High-dimensional analysis of the immune system

Articles specially commissioned by Nature Biotechnology and Nature Immunology discuss new technologies and approaches that enable more detailed and comprehensive analysis of the immune system. Produced with support from Adaptive Biotechnologies.

February Vol. 32, No. 2


Top

2013

Antibody-drug conjugates for cancer therapy

Antibody-drug conjugates for cancer therapy

Several antibody-drug conjugates have been approved for clinical use in a variety of solid and hematological tumors, with many more in human testing. Nature Biotechnology presents a poster by Dario Neri of ETH Zurich describing the various linker strategies, cytotoxic payloads and mechanisms/sites of action of these drugs. Made available with the generous support of Millennium: The Takeda Oncology Company and Seattle Genetics.

December Vol. 31, No. 12


Translating the Microbiome

Translating the Microbiome

Researchers have generated more than 3.5 terabytes of human microbiome genomic information – more than 1,000 times that generated by the Human Genome Project. This Focus highlights progress in microbiome research and how these data might translate into a better understanding of human diseases and rational design of new therapies.

April Vol. 31, No. 4


Top

2012

DNA Sequencing Technology

DNA Sequencing Technology

Performance gains and falling costs have fueled diverse applications of high-throughput DNA sequencing. This focus issue of Nature Biotechnology summarizes the current status of these technologies as applied to life sciences and medical research. Produced with support from Ion Torrent - by Life Technologies.

November Vol. 30, No. 11


Commercializing Biomedical Research

Commercializing Biomedical Research

The present system for commercializing biomedical research remains woefully inefficient and underpowered. This issue of Nature Biotechnology collects several articles that describe alternatives to current pathways for clinical translation of academic discovery.

October Vol. 30, No. 10


Cancer Technologies

Cancer Technologies

Increased understanding of the molecular defects associated with malignancies is opening up new opportunities in diagnosis and therapy. This focus issue of Nature Biotechnology highlights a selection of new technologies that promise to facilitate the development of more effective cancer treatments.

July Vol. 30, No. 7


Plant Technologies

Plant Technologies

Sixteen years after the commercialization of crops produced by traditional transgenic technology, a raft of new approaches are opening new opportunities in plant biotechnology. This focus issue of Nature Biotechnology highlights these technologies and their impact on plant breeding and their impact on regulatory oversight.

March Vol. 30, No. 3


Top

2011

TAL effector nucleases collection

TAL effector nucleases collection

Transcription activator-like (TAL) effector nucleases have emerged as a powerful tool in genome engineering. Several Nature Biotechnology articles on TAL effector nucleases are brought together in this collection produced with support from Cellectis bioresearch.


Nature Biotechnology 15th Anniversary

Nature Biotechnology 15th Anniversary

Nature Biotechnology is 15! We have brought together a collection of commentaries, features and profiles from thought-leaders in the sector that touch upon the issues that are likely to be important in the coming years.

March Vol. 29, No. 3


Top

2010

Epigenetics

Epigenetics

Recent years have seen an explosive increase in our knowledge of such epigenetic mechanisms as chromatin remodeling and DNA methylation in development and disease. This focus issue discusses the current state of the field and how current insights can be translated into practical applications.

October Vol. 28, No. 10


MAQC II

MAQC II

Articles from Nature Biotechnology and The Pharmacogenomics Journal that explore best practices for developing and validating predictive models based on data from gene expression and genotyping microarrays. These report the second phase of a collaboration between industry, academic and government researchers as part of the MicroArray Quality Control (MAQC) consortium.

October Vol. 28, No. 10


PSTC

The Predictive Safety Testing Consortium

The first formal results of the Predictive Testing Safety Consortium, a community-wide effort involving over 190 scientists from industry, non-profit institutions and regulators that set out to qualify nephrotoxicity biomarkers in the preclinical and clinical settings.

May Vol. 28, No. 5


Top

2009

Synthetic Biology

Synthetic Biology

The latest iteration of genetic engineering offers the prospect of the design and construction of new life forms from biological parts, devices and systems. Although still in its infancy, this focus discusses some of the progress in synthetic biology toward practical applications.

December Vol. 27, No. 12


Top

2008

Sequencing

Next-Generation Sequencing

A series of articles that focuses on the massively parallel sequencing technology that are making progress in the quest for a $1000 human genome sequence.

October Vol. 26, No. 10


Top

2007

Antivirals

Antivirals

This issue provides several articles focusing on antiviral therapy. Additional material, brought together in a joint focus with Nature Reviews Drug Discovery supported by our principal sponsor Pfizer and our supporting sponsor Gilead.

December Vol. 25, No. 12


Top

2006

Antibacterials

Antibacterials

A collection of articles from Nature Biotechnology, brought together in a joint focus with Nature Reviews Drug Discovery, on the science and business of antibacterial discovery and development.

December Vol. 24, No. 12


MAQC

MAQC Consortium

This supplement collects together reprints of papers from
Nature Biotechnology reporting the first formal results of a consortium of over 150 regulatory, industrial and academic scientists that set out to conduct a cross-platform analysis of DNA microarray expression data obtained from two, commercially available RNA samples.

October Vol. 24, No. 10s


Microarray Quality Control

Microarray Quality Control

The first formal results of a consortium of over 150 regulatory, industrial and academic scientists that set out to conduct a cross-platform analysis of DNA microarray expression data obtained from two, commercially available RNA samples.

September Vol. 24, No. 9


Diagnostics

Diagnostics

A series of articles that focuses on the scientific, business, regulatory, intellectual property, technology transfer and logistical challenges of accelerating integration of molecular diagnostics into clinical practice and therapy selection.

August Vol. 24, No. 8


10th Anniversary

10th Anniversary

A focus celebrating 10 years of serving the biotech community.

March Vol. 24, No. 3


Top

2005

Antibody Engineering

Antibody Engineering and Manufacture

A focus examining recent progress in antibody research and the commercial and regulatory developments that are shaping it.

September Vol. 23, No. 9


Cell Therapies

Cell Therapies

A focus examining the scientific, legal, regulatory, and commercial context of current cell research for regenerative medicine.

July Vol. 23, No. 7


Top

2004

Health Biotechnology Innovation in Developing Countries

Health Biotechnology Innovation in Developing Countries

The Health Biotechnology Innovation in Developing Countries supplement presents the results of an in-depth study of the health biotechnology sector of seven developing nations. It demonstrates how poorer nations can successfully exploit the biotechnology sector to build their own wealth and improve the well being of their own people. The study is the brainchild of a group of researchers at the Canadian Program on Genomic and Global Health at the University of Toronto Joint Centre for Bioethics.

December Vol. 22, Issue 12s


Biomanufacturing and Bioprocessing

Biomanufacturing and Bioprocessing

As more biotech products receive regulatory approval and the first protein blockbusters come off patent and face generic competition, this focus discusses the challenges for companies manufacturing recombinant proteins.

November Vol. 22, No. 11


Systems biology

Systems biology

A series of articles focuses on potential applications of systems biology to biotechnology.

October Vol. 22, No. 10


Top

2003

Optical imaging

Optical imaging

Brings together a selection of articles on new techniques in optical imaging.

November Vol. 21, No. 11


Nanobio

Nanobiotechnology

Looks at some of the emerging life science applications of nanotechnology and nanoscience.

October Vol. 21, No. 10


Proteomics

Challenges in proteomics

Examines the status of technologies for quantitative protein analysis and the challenges facing efforts to catalogue and characterize the protein content of cells.

March Vol. 21, No. 3


Top

2002

GM crops

Environmental impact of GM crops

Investigates the environmental consequences of cross-fertilization and pollen transfer between GM crops and sexually compatible relatives.

June Vol. 20, No. 6


Top

2000

Industry Trends

Industry Trends

Industry Trends supplement is a collection of both original and updated previously published articles from Aris Persidis' Industry Trends column, which has been published on a regular basis in Nature Biotechnology from 1997 to 1999. Each article provides a concise summary of the historical evolution, current state, challenges, and possible future directions of a biotechnology field. As a collection, the articles provide concise snapshots of biotechnology's fastest-moving areas in a format that allows easy comparison.

October Vol. 18, Issue 10s


Top

1999

BioVision

BioVision

The Nature Biotechnology BioVision supplement contains a diverse set of articles that discuss the potential of biotechnology for improving the quality and duration of life in the coming millennium. Concomitant with the first BioVision meeting in Lyon, France, March 26-29, 1999, the supplement provides a forum for leaders in science, business, and social and cultural thinking to debate the importance of biotechnology in addressing global issues such as population growth, human health, the environment, and their societal, cultural, and political repercussions.

February Vol. 17, Issue 2s


Top

1998

Pharma

Pharmacogenomics

The Nature Biotechnology Pharmacogenomics Supplement brings together articles exploring the importance of genetic variation in drug development that have previously been published in the journal. It captures the excitement surrounding this field, presents the rationale behind diagnostic-led treatment, and outlines the commercial opportunities attendant with the move toward individualized medicine.

FebruaryVol. 16, Issue 2s

Extra navigation

naturejobs

ADVERTISEMENT